ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

NCT06418711 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

132

Enrollment

INDUSTRY

Sponsor class

Stopped Futility

Conditions

MAC Lung Disease
Treatment Refractory MAC Lung Disease
Mycobacterium Infections, Nontuberculous

Interventions

DRUG: Clofazimine Inhalation Suspension
DRUG: Placebo

Sponsor

Mannkind Corporation